IP Library › Granted Patent US 11,339,151
Granted Patent B2
US 11,339,151 · App. 17/528,743 · Granted May 24, 2022

Aliphatic acid amide derivative

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,339,151
App. No.
17/528,743
Filed
Nov 17, 2021
Granted
May 24, 2022
Kind
B2
Art Unit
1624
USPC
514/254.04
Abstract

The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT 2A receptors and serotonin 5-HT 7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R 1a through R 1d , R 2a through R 2d , and R 4a through R 4d are a hydrogen atom and the like; R 3 is alkyl and the like; and Q is a specific bicyclic group.)

Claims (16)

1. A compound which is represented by any one of the following formulae:

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 , which is represented by the following formula:

or a pharmaceutically acceptable salt thereof.